Regulation of COVID19 receptor protein by vitamin D and exercise

Regulation of ACE2 expression in human skeletal muscle by exercise and vitamin D in young males and females

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17980894

Enrollment

Registered

2024-02-26

Start date

2024-03-01

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regulation of COVID19 receptor protein by vitamin D and exercise Not Applicable

Interventions

Thirty healthy young volunteers (15 males and 15 females) will be recruited to test the effects of Vit D3 dietary supplementation or placebo in oral mucosae and skeletal muscle ACE2 protein expression

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Males and females between 18 and 40 years old 2. Physically active, but not submitted to periodized training.

Exclusion criteria

Exclusion criteria: 1. Medical contraindications for maximal exercise 2. Smoking 3. Taking drugs or medications 4. Taking supplements 5. Fainting when seeing blood 6. Not being able to pedal 7. Carrying orthopaedic prosthesis 8. Pregnancy 9. Basal 25 (OH) vitamin D concentration above 80 ng/mL

Design outcomes

Primary

Measure	Time frame
Skeletal muscle protein expression levels of ACE2 measured using western blotting at baseline and at the end of the exercise.	—

Secondary

Measure	Time frame
1. Buccal mucosae protein expression levels of ACE2 measured using western blotting at baseline and at the end of exercise. 2. Skeletal muscle ROS-induced signalling measured using western blotting at baseline and at the end of exercise. 3. Exercise performance (power output) measured using a cycle ergometer, at baseline, during an incremental exercise to exhaustion and during a 10 s sprint 4. Exercise VO2 measured using a metabolic cart, at baseline and during an incremental exercise to exhaustion. 5. Maximal fat oxidation measured using a metabolic cart, during an incremental exercise to exhaustion. 6. Muscle mitochondrial maximal VO2 measured ex vivo measured using high-resolution respirometry at baseline. 7. Skeletal muscle O2 extraction capacity measured using near-infrared spectroscopy, at rest and during incremental exercise to exhaustion. 8. Femoral vein blood gases measured using an intravenous catheter and blood gas analyser at rest and at the end of exercise. 9. Femoral vein acid-base balance measured using an intravenous catheter and blood gas analyser at rest and at the end of exercise. 10. Femoral vein electrolytes measured using an intravenous catheter and blood gas analyser at rest and at the end of exercise. 11. Femoral vein vasoactive peptides measured using ELISA at baseline and after exercise.	—

Measure

Time frame

1. Buccal mucosae protein expression levels of ACE2 measured using western blotting at baseline and at the end of exercise. 2. Skeletal muscle ROS-induced signalling measured using western blotting at baseline and at the end of exercise. 3. Exercise performance (power output) measured using a cycle ergometer, at baseline, during an incremental exercise to exhaustion and during a 10 s sprint 4. Exercise VO2 measured using a metabolic cart, at baseline and during an incremental exercise to exhaustion. 5. Maximal fat oxidation measured using a metabolic cart, during an incremental exercise to exhaustion. 6. Muscle mitochondrial maximal VO2 measured ex vivo measured using high-resolution respirometry at baseline. 7. Skeletal muscle O2 extraction capacity measured using near-infrared spectroscopy, at rest and during incremental exercise to exhaustion. 8. Femoral vein blood gases measured using an intravenous catheter and blood gas analyser at rest and at the end of exercise. 9. Femoral vein acid-base balance measured using an intravenous catheter and blood gas analyser at rest and at the end of exercise. 10. Femoral vein electrolytes measured using an intravenous catheter and blood gas analyser at rest and at the end of exercise. 11. Femoral vein vasoactive peptides measured using ELISA at baseline and after exercise.

—

Countries

Spain

Contacts

Public ContactJose A L Calbet

jose.calbet@ulpgc.es+34 928458868

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026